Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 722.8 USD -0.12% Market Closed
Market Cap: 76B USD

Intrinsic Value

The intrinsic value of one REGN stock under the Base Case scenario is 728.9 USD. Compared to the current market price of 722.8 USD, Regeneron Pharmaceuticals Inc is Undervalued by 1%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

REGN Intrinsic Value
728.9 USD
Undervaluation 1%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Regeneron Pharmaceuticals Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about REGN?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is REGN valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Regeneron Pharmaceuticals Inc.

Explain Valuation
Compare REGN to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Regeneron’s overreliance on Eylea for a significant portion of its revenue poses a major risk, especially as new anti-VEGF therapies and biosimilars could challenge its market share in retinal diseases and pressure pricing.

The company’s R&D pipeline, though robust, demands high and constant levels of investment, raising concerns about the potential for expensive clinical failures and delayed payoffs that could weigh on profitability.

Partnership dynamics with Sanofi, including profit-sharing agreements for core products like Dupixent, may limit Regeneron’s autonomy on strategic decisions while constricting potential upside from certain therapies.

Bull Theses

Despite Eylea’s looming patent expiry, potential label expansions for Dupixent and newer pipeline candidates like pozelimab could diversify revenue sources and provide steady earnings growth.

Regeneron’s proprietary VelociSuite technology platform offers a competitive edge in developing next-generation antibody-based therapies, fueling its strong track record of innovation and drug discovery success.

With multiple late-stage trials in immunology and oncology, Regeneron’s high R&D spend and existing collaborations may translate into meaningful long-term returns if a few key candidates gain regulatory approval.

Show More Less
How do you feel about REGN?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Regeneron Pharmaceuticals Inc

Current Assets 18B
Cash & Short-Term Investments 8.4B
Receivables 5.7B
Other Current Assets 3.9B
Non-Current Assets 22.2B
Long-Term Investments 10.3B
PP&E 5B
Intangibles 1.4B
Other Non-Current Assets 5.5B
Current Liabilities 4.4B
Accounts Payable 903.8m
Accrued Liabilities 3B
Other Current Liabilities 545.6m
Non-Current Liabilities 4.8B
Long-Term Debt 2.7B
Other Non-Current Liabilities 2.1B
Efficiency

Free Cash Flow Analysis
Regeneron Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Regeneron Pharmaceuticals Inc

Revenue
14.2B USD
Cost of Revenue
-2B USD
Gross Profit
12.3B USD
Operating Expenses
-8.4B USD
Operating Income
3.9B USD
Other Expenses
644.3m USD
Net Income
4.6B USD
Fundamental Scores

REGN Profitability Score
Profitability Due Diligence

Regeneron Pharmaceuticals Inc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Positive 3Y Average ROIC
Strong 3Y Average Gross Margin
Healthy Operating Margin
56/100
Profitability
Score

Regeneron Pharmaceuticals Inc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

REGN Solvency Score
Solvency Due Diligence

Regeneron Pharmaceuticals Inc's solvency score is 97/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
97/100
Solvency
Score

Regeneron Pharmaceuticals Inc's solvency score is 97/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

REGN Price Targets Summary
Regeneron Pharmaceuticals Inc

Wall Street analysts forecast REGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for REGN is 774.53 USD with a low forecast of 621.15 USD and a high forecast of 1 063.65 USD.

Lowest
Price Target
621.15 USD
14% Downside
Average
Price Target
774.53 USD
7% Upside
Highest
Price Target
1 063.65 USD
47% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for REGN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

REGN Insider Trading
Buy and sell transactions by insiders

REGN News

Other Videos
What is the Intrinsic Value of one REGN stock?

The intrinsic value of one REGN stock under the Base Case scenario is 728.9 USD.

Is REGN stock undervalued or overvalued?

Compared to the current market price of 722.8 USD, Regeneron Pharmaceuticals Inc is Undervalued by 1%.

Back to Top